Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Omapplusone is a total parenteral nutrition (TPN) product developed by HK inno.N. It is a three-chamber bag (3CB) system designed to provide essential nutrients to patients who cannot receive adequate nutrition through oral or enteral routes. The formulation is an upgraded version of the company's Omap product, containing a lipid emulsion (a blend of soybean oil, medium-chain triglycerides, olive oil, and fish oil rich in omega-3 fatty acids), amino acids, glucose, and electrolytes. The plusone designation signifies the addition of zinc (as zinc gluconate) to the formulation, addressing the common clinical need for trace element supplementation in patients receiving long-term parenteral nutrition. It is available in formulations for both central (Omapplusone Inj) and peripheral (Omapplusone Peri Inj) venous administration.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Omapplusone.